Ask about this productRelated genes to: RAB35 Blocking Peptide
- Gene:
- RAB35 NIH gene
- Name:
- RAB35, member RAS oncogene family
- Previous symbol:
- -
- Synonyms:
- H-ray
- Chromosome:
- 12q24.23
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-29
- Date modifiied:
- 2016-10-05
Related products to: RAB35 Blocking Peptide
Related articles to: RAB35 Blocking Peptide
- Surface proteins enable T follicular helper (Tfh) cells' chemotactic migration toward B cells and subsequent functional interactions, underpinning effective humoral immunity. We showed that geranylgeranyl diphosphate (GGPP), a mevalonate (MVA) pathway-derived isoprenoid, was indispensable for Tfh cell function by maintaining surface protein expression. Either pharmacological inhibition or genetic depletion of geranylgeranyl diphosphate synthase (GGPS1), the enzyme responsible for GGPP biosynthesis, impaired Tfh cell generation. Mechanistically, geranylgeranyl transferase Ⅱ (GGTase Ⅱ) utilizes GGPP to geranylgeranylate RAB GTPases for surface protein expression, as exemplified by RAB35-mediated recycling of the chemokine receptor CXCR5 to the cell surface. Notably, the MVA pathway-GGPS1-GGTase Ⅱ-RAB35 axis in Tfh cells was enhanced by T cell receptor signaling and hyperactivated in autoimmunity. Conversely, the potent statin pitavastatin inhibited this axis to suppress pathogenic Tfh cells and alleviate autoimmunity. Thus, GGPP links the MVA pathway to T cell function via surface protein regulation, revealing a therapeutic target for autoimmune diseases. - Source: PubMed
Publication date: 2026/05/13
Wang LaiJiang JiaoYin HaoyuanWu JunhuiSu XiaoyuMeng LingchangWang LuluBao JingjingLi QilinWei YunboChen ZhianGong JialeiCañete Pablo FZheng MeilingLi WenruiZhou QiongqiongZhao MingYu DiLu Qianjin - Glioblastoma (GBM) cells eliminate temozolomide (TMZ) through extracellular vesicles (EVs), a resistance mechanism independent of DNA damage repair that markedly reduces intracellular drug concentration. However, strategies to block this efflux pathway remain poorly explored. Levetiracetam (LEV), a first-line antiepileptic for GBM patients, suppresses seizures by inhibiting synaptic vesicle release, but its potential role in chemotherapeutic efflux has not been investigated. Chemical proteomics identified RAB5A and CD63 as novel LEV-binding targets, and analyses of TCGA datasets further supported their clinical relevance. Mechanistic studies combining co-immunoprecipitation, immunofluorescence, and in silico modeling revealed LEV-mediated disruption of endosomal trafficking and membrane fusion, thereby inhibiting TMZ efflux. Nanoparticle tracking analysis and electron microscopy were used to evaluate EV release, while LC-MS/MS was employed to quantify TMZ at the subcellular and intratumoral levels. Orthotopic GBM models were used to evaluate therapeutic efficacy. RAB5A and CD63 were identified as dual mediators of LEV activity. LEV competitively bound RAB5A, impairing endosomal maturation and TMZ trafficking. LEV also disrupted CD63-RAB35 interaction, promoting RAB35 proteasomal degradation and suppressing plasma membrane fusion. Collectively, LEV reduced TMZ efflux and synergistically enhanced TMZ cytotoxicity in vitro, while in orthotopic models the combination therapy inhibited tumor growth, was accompanied by immune microenvironment remodeling, and prolonged survival. - Source: PubMed
Publication date: 2026/05/06
Zhao JixingLi MingkunZhang QinranLi BoyanQi YanhuaGao ZijieWang QingtongZhao RongrongZhao HongyuZhang KailiangXue HaoLi Gang - Kratom (Mitragyna speciosa) is a traditional Southeast Asian botanical long used for alleviating pain and boosting energy. Its chief bioactive compound, mitragynine (MG), exhibits both opioid-like and stimulant properties and has prompted interest in its potential role in pain management and opioid withdrawal support. However, its safety profile and underlying mechanisms remain incompletely understood. This systematic review critically synthesizes preclinical evidence on kratom's molecular, pharmacological, and epigenetic effects. Guided by PRISMA 2020 criteria, studies indexed in Scopus and Web of Science (2000-2024) were analyzed, focusing on receptor activity, intracellular signaling, and gene regulation in in vitro and in vivo models. Among 20 eligible studies, key findings indicate that kratom alkaloids engage μ-opioid, adrenergic, and serotonergic receptors; modulate dopaminergic and glutamatergic systems; and exert anti-inflammatory and analgesic effects. Under chronic exposure followed by withdrawal, MG was associated with reduced histone acetylation and increased HDAC2 expression, while Rab35 emerged as a potential withdrawal-associated biomarker. MG also inhibited cardiac ion channels and altered CYP450 enzyme expression, highlighting safety concerns related to cardiotoxicity and drug-drug interactions. Despite these mechanistic insights, limitations in pharmacokinetic data, standardized dosing, and long-term safety preclude clinical application. Future research should prioritize controlled human studies, omics-driven biomarker discovery, and evidence-based regulatory evaluation to clarify kratom's therapeutic potential and risk profile. - Source: PubMed
Publication date: 2026/04/16
Misnan EdyhamHasbullah Nur Zahidah AqilahAbd Rashid RusdiMohd Shah AishahSim Maw Shin - Endometrial carcinoma (EC) is a common malignancy of the female reproductive system. Rab35 is widely recognized as an oncogenic driver and has been implicated in the progression of various malignant tumors. However, its regulatory mechanism and pathobiological roles in EC remain unclear. - Source: PubMed
Publication date: 2026/02/26
Yang EryanWang YindanMao WenxinCui TiaoxiaLi MeiyueZhao ShuangshuangZhang JingyingYan YeChen YuanyuanTian WenyanWang Yingmei - Trogocytosis is a form of cellular cannibalism in which a cell "bites" off pieces of another cell. Here, we investigate the molecular mechanisms of a developmentally programmed trogocytic event that occurs when endodermal cells bite off and digest pieces of primordial germ cells (PGCs) called lobes. Through a genetic screen, we identify the Rab family small GTPase as a central regulator of trogocytosis and show that its function is required in both biting (endodermal) and bitten (PGC) cells. Within endodermal cells, RAB-35 enriches around trogocytosed PGC lobes, promotes the removal of phosphatidylinositol 4,5-bisphosphate (PIP ), and is required for lobe digestion. By contrast, we show that RAB-35 within PGCs works with the ESCRT complex to promote scission of the PGC lobe from the cell body. Our findings identify a new regulator of trogocytosis that has distinct functions in the biting and bitten cells and provide evidence that the bitten cell contributes to the scission of its own membrane. - Source: PubMed
Publication date: 2026/02/22
Manikas JuliePopovsky LiamAbdu YusuffNance Jeremy